Compass Pathways (NASDAQ:CMPS) Issues Quarterly Earnings Results, Misses Expectations By $0.20 EPS

Compass Pathways (NASDAQ:CMPS) announced its quarterly earnings data on Tuesday. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.20), Zacks reports.

Compass Pathways Trading Up 7.7%

Shares of NASDAQ:CMPS opened at $5.62 on Thursday. Compass Pathways has a 52-week low of $2.25 and a 52-week high of $8.90. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The company has a market cap of $539.63 million, a P/E ratio of -1.82 and a beta of 1.90. The stock’s 50-day moving average is $6.74 and its 200-day moving average is $6.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CMPS. Persistent Asset Partners Ltd acquired a new position in shares of Compass Pathways in the 4th quarter worth approximately $38,000. Advisory Services Network LLC acquired a new stake in Compass Pathways in the 3rd quarter valued at $41,000. Northeast Financial Consultants Inc acquired a new position in Compass Pathways during the second quarter worth $59,000. MML Investors Services LLC acquired a new position in Compass Pathways during the fourth quarter worth $69,000. Finally, Raymond James Financial Inc. lifted its holdings in shares of Compass Pathways by 82.7% during the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after acquiring an additional 6,228 shares during the period. Institutional investors own 46.19% of the company’s stock.

Key Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Morgan Stanley kept an Overweight rating on CMPS while trimming its price target to $16 (from $18). The new target implies roughly a 185% upside from the current price level, which can attract buyers and support upward momentum. Benzinga
• Neutral Sentiment: Company released its fourth-quarter and full-year 2025 results and business highlights via BusinessWire; management emphasized the progress of COMP360 and broader development milestones. The release provides context for results and pipeline progress but did not override the EPS miss. BusinessWire
• Neutral Sentiment: Multiple short-interest reports for March show data anomalies (reported totals of “0 shares” and NaN changes). The reported days-to-cover/short-interest ratio reads as 0.0, which is likely a reporting error rather than a real change in short positioning. Investors should treat these figures cautiously until corrected filings are available. (Sources aggregated)
• Negative Sentiment: Q4 EPS missed consensus: CMPS reported a loss per share of ($0.59) vs. the expected ($0.39), missing by $0.20. An EPS miss typically pressures biotech names, as it raises questions about near-term financial performance and cash runway. Press Release

Analyst Ratings Changes

Several analysts recently issued reports on CMPS shares. Royal Bank Of Canada increased their price objective on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Canaccord Genuity Group boosted their target price on Compass Pathways from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Wednesday, January 21st. Morgan Stanley reduced their price target on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, HC Wainwright increased their price objective on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.88.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.